Bluejay Diagnostics (Bluejay Diagnostics) Change In Payables And Accrued Expense : $-0.27 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Change In Payables And Accrued Expense?

Bluejay Diagnostics's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $-1.22 Mil. It means Bluejay Diagnostics's Accounts Payable & Accrued Expense declined by $1.22 Mil from Sep. 2023 to Dec. 2023 .

Bluejay Diagnostics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-0.27 Mil. It means Bluejay Diagnostics's Accounts Payable & Accrued Expense declined by $0.27 Mil from Dec. 2022 to Dec. 2023 .

Bluejay Diagnostics Change In Payables And Accrued Expense Historical Data

The historical data trend for Bluejay Diagnostics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bluejay Diagnostics Change In Payables And Accrued Expense Chart

Bluejay Diagnostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

-0.02

0.54

0.63

-0.27

Bluejay Diagnostics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial											0.27	-0.33	0.37	0.91	-1.22

Bluejay Diagnostics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27 Mil.

Bluejay Diagnostics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720

Website

https://www.bluejaydx.com

Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.

Executives

Svetlana Dey	director, 10 percent owner	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey	director, 10 percent owner, officer: Chief Technology Officer	360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally	officer: CFO	66 MELANIE LANE, SYOSSET NY 11791
Jason Cook	officer: Chief Technology Officer	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher	officer: Chief Financial Officer	67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth	director, 10 percent owner	4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder	officer: Chief Financial Officer	360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani	director	C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman	director	109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase	director	39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089